Each filer's latest filing for 880881107 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
| BlackRock, Inc. 13G/A | 6.8% |
2/5/2025
Event 12/31/2024
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (10) | ||||
| Schonfeld Strategic Advisors LLC 13G/A | 4.9% |
5/15/2025
Event 3/31/2025
|
||
|
Orbimed Advisors LLC
13D/A
|
4.8% |
11/5/2025
Event 11/3/2025
|
||
| Orbimed Advisors LLC | 4.8% | |||
| Orbimed Capital GP VII LLC | 3.1% | |||
| OrbiMed Asia GP III, L.P. | 1.2% | |||
| OrbiMed Advisors III Ltd | 1.2% | |||
| OrbiMed Genesis GP LLC | 0.5% | |||
|
Citadel Advisors LLC
13G/A
|
4.1% |
2/14/2025
Event 12/31/2024
|
||
| Citadel Advisors LLC | 3.9% | |||
| Citadel Advisors Holdings LP | 3.9% | |||
| Citadel GP LLC | 3.9% | |||
| Citadel Securities LLC | 0.2% | |||
| Citadel Securities Group LP | 0.2% | |||
| Citadel Securities GP LLC | 0.2% | |||
| Kenneth Griffin | 4.1% | |||
|
Deep Track Capital, LP
13G/A
|
3.0% |
2/13/2026
Event 12/31/2025
|
||
| Deep Track Capital, LP | 3.0% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 3.0% | |||
| David Kroin | 3.0% | |||
|
Vivo Opportunity Fund Holdings, L.P.
13G/A
|
2.5% |
2/13/2026
Event 1/31/2025
|
||
| Vivo Capital Fund VIII, L.P. | 0.9% | |||
| Vivo Capital Surplus Fund VIII, L.P. | 0.1% | |||
| Vivo Capital VIII, LLC | 1.0% | |||
| Vivo Opportunity Fund Holdings, L.P. | 2.5% | |||
| Vivo Opportunity, LLC | 2.5% | |||
| Vivo Opportunity Cayman Fund, L.P. | 0.2% | |||
| Vivo Opportunity Cayman, LLC | 0.2% | |||
|
Adage Capital Management, L.P.
13G/A
|
1.8% |
5/13/2026
Event 3/31/2026
|
||
| Adage Capital Management, L.P. | 1.8% | |||
| Robert Atchinson | 1.8% | |||
| Phillip Gross | 1.8% | |||
|
Commodore Capital LP
13G/A
|
1.4% |
2/17/2026
Event 12/31/2025
|
||
| Commodore Capital LP | 1.4% | |||
| Commodore Capital Master LP | 1.4% | |||
| Robert Egen Atkinson | 1.4% | |||
| Michael Kramarz | 1.4% | |||
|
Soleus Capital Master Fund, L.P.
13G/A
|
0.2% |
2/12/2026
Event 12/31/2025
|
||
| Soleus Capital Master Fund, L.P. | 0.2% | |||
| Soleus Capital, LLC | 0.2% | |||
| Soleus Capital Group, LLC | 0.2% | |||
| Soleus Capital Management, L.P. | 0.2% | |||
| Soleus GP, LLC | 0.2% | |||
| Guy Levy | 0.2% | |||
| Morgan Stanley 13G/A | 0% |
6/5/2026
Event 5/31/2026
|
||
| Vanguard Group Inc 13G/A | 0% |
3/27/2026
Event 3/13/2026
|
||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 2 | 12.5 k | $660k |
| 2026 Q1 | 328 | 125 M | $6.56B |
| 2025 Q4 | 250 | 123 M | $4.95B |
| 2025 Q3 | 143 | 88.6 M | $666M |
| 2025 Q2 | 131 | 83.1 M | $310M |
| 2025 Q1 | 141 | 83.1 M | $230M |
| 2024 Q4 | 158 | 86.1 M | $477M |
| 2024 Q3 | 158 | 79.5 M | $663M |
| 2024 Q2 | 127 | 65.6 M | $447M |
| 2024 Q1 | 113 | 63.2 M | $415M |
| 2023 Q4 | 104 | 63.6 M | $413M |
| 2023 Q3 | 95 | 61.7 M | $310M |
| 2023 Q2 | 105 | 57.7 M | $505M |
| 2023 Q1 | 80 | 53.2 M | $630M |
| 2022 Q4 | 66 | 49.7 M | $506M |
| 2022 Q3 | 46 | 30.3 M | $178M |
| 2022 Q2 | 43 | 14.7 M | $36.6M |
| 2022 Q1 | 45 | 16.8 M | $50.0M |
| 2021 Q4 | 38 | 16.5 M | $117M |
| 2021 Q3 | 35 | 16.7 M | $174M |
| 2021 Q2 | 37 | 16.6 M | $204M |
| 2021 Q1 | 43 | 17.9 M | $394M |